Latest News and Press Releases

SAN FRANCISCO, March 08, 2018 (GLOBE NEWSWIRE) -- via OTC PR WIRE--Elto Pharma, Inc., a specialty pharmaceutical, clinical-stage wholly-owned subsidiary of Amarantus Bioscience Holdings, Inc....

SAN FRANCISCO, March 05, 2018 (GLOBE NEWSWIRE) -- Via OTC PR Wire -- Elto Pharma, Inc., an orphan specialty pharmaceutical, clinical-stage wholly-owned subsidiary of Amarantus Bioscience Holdings,...

Allowed claims include the treatment of Type 1 and Type 2 DiabetesPatent protects exclusivity for MANF in diabetes inthe US into 2032 SAN FRANCISCO, March 01, 2018 (GLOBE NEWSWIRE) -- via OTC PR...

At least 96% of eligible securities participating in Tender ExchangeCEO to present at BIOCOM Global Life Science Partnering Conference in San Diego SAN FRANCISCO, Feb. 26, 2018 (GLOBE NEWSWIRE) --...

SAN FRANCISCO, Jan. 29, 2018 (GLOBE NEWSWIRE) -- Via OTC PR Wire -- Amarantus Bioscience Holdings, Inc. (OTCPK:AMBS), a US-based biotechnology holding company with wholly-owned subsidiaries...

Patent Issuance Opens Potential to genetically modify cells used to produce ESS Peer-Reviewed publication demonstrates improved donor cosmetic skin color matching of melanocytes-implanted ESS vs....

Convertible securities holders grant 45-day extension to complete Tender Exchange     Elto Pharma recruiting seasoned management to lead "Go-Public" transaction     Management...

Patent Issuance Opens Potential to genetically modify cells used to produce ESSPeer-Reviewed publication demonstrates improved donor cosmetic skin color matching of melanocytes-implanted ESS vs....

Patents extend MANF Therapeutics' exclusivity for use of MANF as a treatment and a biomarker for beta cell disorders in Europe and China into 2032List of diseases covered by patents include Type-1...

Patents extend MANF Therapeutics' exclusivity for MANF and CDNF treatment of retinal disorders in Europe into 2031Literature Watch "Super-MANF" article published in American Journal of Transplantation...